CHM.CN Stock Surges 900% on CNQ: Waverunner Capital Gains Apr 2026

CHM.CN stock has delivered a stunning 900% gain in recent trading, with shares climbing to C$0.05 on the CNQ exchange. Waverunner Capital Inc., the North Vancouver-based venture capital firm, is experiencing extreme volatility as investors react to the company’s repositioning. The stock previously traded at just C$0.005, making this move one of the most dramatic swings in the healthcare sector. With a market cap of C$37.2 million and 744 million shares outstanding, CHM.CN remains a highly speculative play. This surge reflects renewed interest in the company’s investment strategy across early-stage ventures, renewable energy, and biotechnology sectors.

CHM.CN Stock Price Action and Market Movement

The 900% jump in CHM.CN stock represents one of the most aggressive single-day moves on the CNQ exchange. Shares moved from C$0.005 to C$0.05, with both the day low and day high sitting at C$0.05, indicating strong buying pressure throughout the session. The 50-day moving average stands at C$0.0424, while the 200-day average is C$0.0481, suggesting the stock has traded significantly higher historically.

Year-to-date performance shows the stock remains well below its 52-week high of C$0.10, though it has held above the C$0.05 floor. Average daily volume of 28,908 shares indicates relatively thin liquidity, which amplifies price swings. Track CHM.CN on Meyka for real-time updates on this volatile mover. The extreme volatility reflects the speculative nature of venture capital investments and the company’s recent strategic pivot.

Waverunner Capital Inc. Business Model and Strategy

Waverunner Capital Inc. operates as a venture capital firm focused on early-stage investments, seed funding, and bridge financing across Europe and North America. The company targets equity investments between C$500,000 and C$1 million, with enterprise values ranging from C$2 million to C$5 million. Its portfolio spans renewable energy (wind and solar), plant-based wellness, consumer-targeted biotechnology, and resource sectors.

The company rebranded from Chemistree Technology Inc. to Waverunner Capital Inc. in June 2024, signaling a strategic shift away from its previous focus. CEO Karl Eric Kottmeier leads the firm from its headquarters at 828 Harbourside Drive in North Vancouver, British Columbia. Waverunner makes investments through both its own balance sheet and personal capital, providing flexibility in deployment. Founded in 2008, the company has evolved significantly to capture opportunities in high-growth venture markets.

Financial Metrics and Valuation Concerns

CHM.CN’s financial profile reveals significant challenges beneath the surface of recent price gains. The company reports negative earnings per share of -C$0.01 and a negative PE ratio of -5.0, indicating ongoing losses. Net income per share stands at -C$0.0595, while operating cash flow per share is -C$0.0045, both deeply negative metrics.

The current ratio of just 0.097 signals severe liquidity stress, with current liabilities far exceeding current assets. Book value per share is negative at -C$0.1422, suggesting shareholders’ equity has eroded. Working capital deficit reaches -C$520,504, and the debt-to-assets ratio of 1.41 indicates the company carries more debt than assets. These metrics explain why CHM.CN remains highly speculative despite the recent price surge. Investors should recognize that extreme volatility often masks fundamental weakness.

Market Sentiment and Trading Activity

The 900% surge in CHM.CN reflects speculative buying rather than fundamental improvement. Average volume of 28,908 shares demonstrates thin liquidity, making large percentage moves possible on modest dollar volume. The stock’s five-day performance shows a 400% gain, indicating sustained buying pressure over multiple sessions.

Long-term performance tells a different story: the stock has declined 80.4% over five years and 93.3% over ten years, with an all-time loss of 98.97% from peak levels. This pattern suggests CHM.CN attracts momentum traders and speculators rather than value investors. The healthcare sector classification masks the company’s true venture capital nature. Meyka AI rates CHM.CN with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

CHM.CN stock’s 900% surge to C$0.05 captures attention but demands careful scrutiny. While Waverunner Capital Inc. operates in attractive venture capital markets spanning renewable energy and biotechnology, the company’s financial fundamentals remain deeply challenged. Negative earnings, severe liquidity stress, and eroded shareholder equity paint a concerning picture beneath the price action. The extreme volatility reflects speculative trading in a thinly-traded security rather than genuine business improvement. Investors considering CHM.CN should recognize this as a high-risk, speculative position suitable only for those with substantial risk tolerance. The company’s rebranding and …

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.